4.7 Article

Notch-mediated induction of N-cadherin and α9-integrin confers higher invasive phenotype on rhabdomyosarcoma cells

期刊

BRITISH JOURNAL OF CANCER
卷 107, 期 8, 页码 1374-1383

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2012.411

关键词

rhabdomyosarcoma; Notch; NCAD; ITGA9; invasion; soft-tissue sarcomas

类别

资金

  1. Institut Catala d'Oncologia (ICO)
  2. Instituto de Salud Carlos III [RD06/0020/1021, PI11/00740]
  3. Fundacio la Marato de TV3
  4. Asociacion Espanola Contra el Cancer
  5. Fundacio SMALL
  6. Fundacio A. BOSCH

向作者/读者索取更多资源

BACKGROUND: Rhabdomyosarcoma (RMS) is the commonest type of soft-tissue sarcoma in children. Patients with metastatic RMS continue to have very poor prognosis. Recently, several works have demonstrated a connection between Notch pathway activation and the regulation of cell motility and invasiveness. However, the molecular mechanisms of this possible relationship remain unclear. METHODS: The Notch pathway was manipulated pharmacologically and genetically. The mRNA changes were analysed by quantitative PCR and protein variations by western blot and immunofluorescence. Finally, the capabilities of RMS cells to adhere, heal a wound and invade were assessed in the presence of neuronal cadherin (N-cadherin)- and alpha 9-integrin-blocking antibodies. RESULTS: Cells treated with gamma-secretase inhibitor showed lower adhesion capability and downregulation of N-cadherin and alpha 9-integrin. Genetic manipulation of the Notch pathway led to concomitant variations in N-cadherin and alpha 9-integrin. Treatment with anti-N-cadherin-blocking antibody rendered marked inhibition of cell adhesion and motility, while anti-alpha 9-integrin-blocking antibody exerted a remarkable effect on cell adhesion and invasiveness. CONCLUSION: Neuronal cadherin and alpha 9-integrin are postulated as leading actors in the association between the Notch pathway and promotion of cell adhesion, motility and invasion, pointing to these proteins and the Notch pathway itself as interesting putative targets for new molecular therapies against metastases in RMS. British Journal of Cancer (2012) 107, 1374-1383. doi:10.1038/bjc.2012.411 www.bjcancer.com Published online 13 September 2012 (C) 2012 Cancer Research UK

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据